Is Panacea Biotec overvalued or undervalued?

As of 13 November 2020, the valuation grade for Panacea Biotec has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued, given its negative PE ratio of -61.96 and EV to EBITDA ratio of -103.02, which are starkly contrasting with its peers. The Price to Book Value stands at 3.30, suggesting that the market is pricing the company at a premium despite its financial struggles.
In comparison to its peers, Panacea Biotec's ratios are considerably worse; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight the challenges Panacea Biotec faces in the market. Additionally, while the company has shown impressive returns over the past year at 252.56%, this performance is not enough to justify its current valuation in light of its financial metrics.